ERJ Open Res. 2026 Mar 9;12(2):00724-2025. doi: 10.1183/23120541.00724-2025. eCollection 2026 Mar.
ABSTRACT
BACKGROUND: Little is known about the effects of portable supplemental oxygen therapy (SOT) to improve exercise performance in highlanders at risk for high-altitude pulmonary hypertension (HAPH). We aimed to investigate whether SOT improves the 6-min walk distance (6MWD) and reduces perceived dyspnoea in highlanders at risk for HAPH.
METHODS: In a pragmatic randomised open-label crossover trial, adult highlanders, living >2500 m, with a peak tricuspid regurgitation velocity >2.8 m·s-1 corresponding to a tricuspid regurgitation pressure gradient (TRPG) ≥31 mmHg by echocardiography were included. Highlanders were randomised to perform two 6-min walk tests at 3250 m with and without SOT (50 mL pulse volume, via nasal cannula, provided by a portable device). The primary outcome was the effect of SOT on the 6MWD compared with ambient air (air). Secondary outcomes were vital parameters and dyspnoea assessed by the Borg Category-Ratio 10 (CR10) Scale with SOT versus air.
RESULTS: 47 highlanders (44% male, mean±sd age of 52±12 years, TRPG of 41±10 mmHg and oxygen saturation (S pO2 ) of 88±3%) were included. SOT did not improve 6MWD compared with air (457±90 m versus 475±84 m; mean difference with SOT of -18 m (95% CI -30-8; p=0.241)). End-exercise dyspnoea was significantly lower with SOT compared with air, along with reduced heart rate and higher S pO2 .
CONCLUSION: In hypoxaemic highlanders at risk for HAPH, portable low-dose SOT did not improve 6MWD, despite lower dyspnoea perception, lower heart rates and higher S pO2 at end-exercise. This indicates that low-dose SOT oxygen, as commonly applied in various clinical settings, does not increase 6MWD. Whether it reduces cardiovascular stress during exercise needs to be further studied.
PMID:41809866 | PMC:PMC12969681 | DOI:10.1183/23120541.00724-2025